of American Pathologists and a Fellow of the Royal Society of Medicine. Currently, she is the Chair of the American Joint Committee on Cancer (AJCC), serves on the Executive Committee of the Commission on Cancer of the American College of Surgeons, and serves as the Pathology Section Editor for Cancer. She is a past Chair of the Cancer Committee of the College of American Pathologists and was Editor of the first edition of the CAP Cancer Protocols (Reporting on Cancer Specimens) used as standards for COC accreditation. Among her awards are the ISBER Award for Outstanding Achievement in Biobanking, the NIH Director’s Award, the NIH Award of Merit, and the CAP Frank W. Hartman Award. She has published more than 500 original scientific papers, reports, review articles, books, and abstracts.

Louis J. DeGennaro, Ph.D. (Workshop Co-Chair), is Executive Vice President and Chief Mission Officer, LLS. As Chief Mission Officer, Dr. DeGennaro’s current responsibilities include oversight of all LLS mission functions: Public Policy, Patient Services, and Research with the goal of effectively deploying resources in pursuit of the LLS mission to cure leukemia, lymphoma, and myeloma and to improve the quality of life for patients and their families. The Society’s mission budget exceeds $100 million annually. Dr. DeGennaro has more than 25 years of research, drug development, and executive management experience in academic and private-sector settings. He received his Ph.D. in biochemistry from the University of California, San Francisco, and did his postdoctoral research at Yale University School of Medicine. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School. Dr. DeGennaro’s private-sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, New Jersey, where his department contributed to the development of pantoprazole (Protonix®) to treat acid reflux disease, Effexor (Venlafaxine®) for anxiety and depression, and Mylotarg® for leukemia; executive vice president for research and development, SynX Pharma, Inc., in Toronto, Canada, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, Inc., Omaha, Nebraska, where he helped develop an FDA-cleared diagnostic test for AIDS/HIV.

Margaret Anderson, M.S., is Executive Director of FasterCures/The Center for Accelerating Medical Solutions, defining the organization’s strategic priorities and positions on key issues, developing its programmatic portfolio, and managing its operations. Prior to her appointment as



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement